IL6 and COVID-19: Since the outbreak of this pandemic, many studies, including results from University Hospital Split, have shown that IL-6 could be used as a prognostic factor for the severity and mortality of COVID-19, and this could be helpful in the early selection of patients who are good candidates for tocilizumab/baricitinib therapy.